Mega Lifesciences (Thailand) Performance
| MEGA Stock | THB 32.00 0.25 0.78% |
The company secures a Beta (Market Risk) of -0.26, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Mega Lifesciences are expected to decrease at a much lower rate. During the bear market, Mega Lifesciences is likely to outperform the market. At this point, Mega Lifesciences Public has a negative expected return of -0.0408%. Please make sure to verify Mega Lifesciences' information ratio, total risk alpha, and the relationship between the coefficient of variation and jensen alpha , to decide if Mega Lifesciences Public performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Mega Lifesciences Public has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent forward-looking signals, Mega Lifesciences is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 1 B | |
| Total Cashflows From Investing Activities | -264.7 M |
Mega |
Mega Lifesciences Relative Risk vs. Return Landscape
If you would invest 3,349 in Mega Lifesciences Public on December 26, 2024 and sell it today you would lose (124.00) from holding Mega Lifesciences Public or give up 3.7% of portfolio value over 90 days. Mega Lifesciences Public is generating negative expected returns and assumes 2.0621% volatility on return distribution over the 90 days horizon. Simply put, 18% of stocks are less volatile than Mega, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Mega Lifesciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mega Lifesciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mega Lifesciences Public, and traders can use it to determine the average amount a Mega Lifesciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0198
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MEGA |
Estimated Market Risk
| 2.06 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mega Lifesciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mega Lifesciences by adding Mega Lifesciences to a well-diversified portfolio.
Mega Lifesciences Fundamentals Growth
Mega Stock prices reflect investors' perceptions of the future prospects and financial health of Mega Lifesciences, and Mega Lifesciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mega Stock performance.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 38.59 B | |||
| Shares Outstanding | 871.87 M | |||
| Price To Book | 4.70 X | |||
| Price To Sales | 2.68 X | |||
| Revenue | 14.14 B | |||
| EBITDA | 2.58 B | |||
| Cash And Equivalents | 1.42 B | |||
| Cash Per Share | 1.63 X | |||
| Total Debt | 1.23 B | |||
| Debt To Equity | 21.10 % | |||
| Book Value Per Share | 9.78 X | |||
| Cash Flow From Operations | 2.73 B | |||
| Earnings Per Share | 2.68 X | |||
| Total Asset | 13.27 B | |||
| Retained Earnings | 2.03 B | |||
| Current Asset | 5.87 B | |||
| Current Liabilities | 2.72 B | |||
About Mega Lifesciences Performance
By examining Mega Lifesciences' fundamental ratios, stakeholders can obtain critical insights into Mega Lifesciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Mega Lifesciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast moving consumer goods. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited. MEGA LIFESCIENCES operates under Drug Manufacturers - Major classification in Thailand and is traded on Stock Exchange of Thailand.Things to note about Mega Lifesciences Public performance evaluation
Checking the ongoing alerts about Mega Lifesciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mega Lifesciences Public help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mega Lifesciences generated a negative expected return over the last 90 days | |
| About 61.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Mega Lifesciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mega Lifesciences' stock is overvalued or undervalued compared to its peers.
- Examining Mega Lifesciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mega Lifesciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mega Lifesciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mega Lifesciences' stock. These opinions can provide insight into Mega Lifesciences' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Mega Stock
Mega Lifesciences financial ratios help investors to determine whether Mega Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mega with respect to the benefits of owning Mega Lifesciences security.